Swiss medicines regulator Swissmedic was expected to approve two drugs for Alzheimer‘s disease. But in late January it only approved one, leaving patients in Switzerland with fewer treatment options than in many countries. What happened? For two and a half years, doctors in Switzerland have been eagerly awaiting a decision from Swissmedic on two new drugs for early-stage Alzheimer’s disease – Leqembi (lecanemab) and Kisunla (donanemab). These are the first drugs to slow cognitive decline and address one potential underlying cause of the disease – amyloid plaques in the brain. Leqembi garnered more media attention as it was approved by the US regulator in July 2023 – a year before Kisunla. Since then, more than 50 countries have approved it. Both drugs were submitted to Swissmedic for approval within six months of each other in 2023. News finally arrived in early February that Swissmedic had authorised Kisunla, Eli Lilly’s treatment for early-stage Alzheimer’s disease, on January 22 ...
Full story here
Are you the author?
Previous post
See more for
Next post
Tags: Featured,newsletter
Home › 3) Swiss Markets and News › 3.) Swissinfo Business and Economy › Switzerland’s bitter-sweet news for Alzheimer’s patients
Previous post
Next post
Switzerland’s bitter-sweet news for Alzheimer’s patients
Published on February 27, 2026
Permanent link to this article: https://snbchf.com/2026/02/switzerland-news-alzheimer-patients/
Receive a Daily Mail from this Blog
Live Currency Cross Rates
On Swiss National Bank
-
SNB Sight Deposits: increased by 5.2 billion francs compared to the previous week
12 days ago -
SNB’s Chairman Schlegel: A few months of negative inflation wouldn’t be a problem
2026-01-21 -
2025-07-31 – Interim results of the Swiss National Bank as at 30 June 2025
2025-07-31 -
SNB Brings Back Zero Percent Interest Rates
2025-06-26 -
Hold-up sur l’eau potable (2/2) : la supercherie de « l’hydrogène vert ». Par Vincent Held
2025-06-24
Main SNB Background Info
-
SNB Sight Deposits: increased by 5.2 billion francs compared to the previous week
12 days ago -
The Secret History Of The Banking Crisis
2017-08-14 -
SNB Balance Sheet Now Over 100 percent GDP
2016-08-29 -
The relationship between CHF and gold
2016-07-23 -
CHF Price Movements: Correlations between CHF and the German Economy
2016-07-22
Featured and recent
-
100K EUR bald nichts mehr wert? -
‘Money laundering’ Swiss MBaer bank shut down -
Swiss anti-GMO initiative handed in at Bern -
Massachusetts 1690: The First Western Fiat Experiment
-
How Ray Dalio Learned to Invest -
Was passiert mit 10.000€, wenn du sie liegen lässt? -
Swiss president calls for European economic cooperation -
What Is the State of the Union?
-
ACHTUNG: Casting-Skandal bei SWR Wahlarena! -
Insurer Swiss Re posts significantly higher profits
More from this category
‘Money laundering’ Swiss MBaer bank shut down27 Feb 2026
Swiss anti-GMO initiative handed in at Bern27 Feb 2026
- Massachusetts 1690: The First Western Fiat Experiment
27 Feb 2026
Swiss president calls for European economic cooperation27 Feb 2026
- What Is the State of the Union?
27 Feb 2026
Insurer Swiss Re posts significantly higher profits27 Feb 2026
Swiss economy rebounded slightly Q4 202527 Feb 2026
- Godfrey Bloom: The Futility of War
27 Feb 2026
Switzerland’s bitter-sweet news for Alzheimer’s patients27 Feb 2026
- The Executive’s Legal Limits on Tariffs and Foreign Policy
27 Feb 2026
- ‘Nature-Al’ Entrepreneurship: Being Green Without the State
26 Feb 2026
- The Bill of Rights Against the States
26 Feb 2026
- Massachusetts 1690: The First Western Fiat Experiment
26 Feb 2026
Swiss MBaer bank labelled money laundering threat by US26 Feb 2026
Switzerland freezes CHF687m linked to Maduro’s Venezuelan circle26 Feb 2026
Swiss bank Edmond de Rothschild monitors Epstein links26 Feb 2026
- In Defense of National Borders
26 Feb 2026
- We Act in a World of Uncertainty, Not Probabilities
26 Feb 2026
WEF boss resigns over Epstein links26 Feb 2026
- How the Bill of Rights Became Weaponized Against the States
26 Feb 2026













